

# WHO consolidated guidelines on tuberculosis

Module 3: Diagnosis

Rapid diagnostics for  
tuberculosis detection

2021 update



World Health  
Organization



# WHO consolidated guidelines on tuberculosis

Module 3: Diagnosis

**Rapid diagnostics for  
tuberculosis detection**

2021 update

WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update

ISBN 978-92-4-002941-5 (electronic version)

ISBN 978-92-4-002942-2 (print version)

© **World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO consolidated guidelines on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# Contents

Acknowledgements.....	vii
Abbreviations and acronyms.....	xvi
Definitions.....	xviii
Executive summary.....	xix
<b>1. Introduction.....</b>	<b>1</b>
1.1. Background.....	1
1.2. Scope of the document.....	4
1.3. Target audience.....	4
<b>2. Recommendations.....</b>	<b>5</b>
2.1. Initial diagnostic tests for diagnosis of TB with drug-resistance detection.....	5
Xpert MTB/RIF and Xpert MTB/RIF Ultra assays.....	5
Truenat MTB, MTB Plus and MTB-RIF Dx assays.....	43
Moderate complexity automated NAATs for detection of TB and resistance to rifampicin and isoniazid <b>NEW</b> .....	50
2.2. Initial diagnostic tests for diagnosis of TB without drug-resistance detection.....	67
Loop-mediated isothermal amplification.....	67
Lateral flow urine lipoarabinomannan assay.....	74
2.3. Follow on diagnostic tests for detection of additional drug-resistance.....	87
Low complexity automated NAATs for detection of resistance to isoniazid and second-line anti-TB agents <b>NEW</b> .....	87
First-line LPAs.....	101
Second-line LPAs.....	108
High complexity reverse hybridization-based NAATs for detection of pyrazinamide resistance <b>NEW</b> .....	115
<b>References.....</b>	<b>125</b>

<b>Annex 1: Guideline development methods</b> .....	<b>129</b>
<b>Annex 2: Conflict of interest assessment for Guideline Development Group and External Review Group members</b> .....	<b>133</b>

### **Web Annex 1. List of studies included in systematic reviews**

- Web Annex 1.1 Xpert MTB/RIF and Xpert Ultra
- Web Annex 1.2 Truenat MTB, MTB Plus, MTB-RIF Dx
- Web Annex 1.3 Moderate complexity automated NAATs
- Web Annex 1.4 Loop-mediated isothermal amplification (TB-LAMP)
- Web Annex 1.5 Lateral flow urine lipoarabinomannan assay (LF-LAM)
- Web Annex 1.6 Low complexity automated NAATs
- Web Annex 1.7 First-line line probe assay (FL-LPA)
- Web Annex 1.8 Second-line line probe assay (SL-LPA)
- Web Annex 1.9 High complexity reverse hybridization-based NAATs

### **Web Annex 2. GRADE profiles**

- Web Annex 2.1 Xpert MTB/RIF and Xpert Ultra
- Web Annex 2.2 Truenat MTB, MTB Plus, MTB-RIF Dx
- Web Annex 2.3 Moderate complexity automated NAATs
- Web Annex 2.4 Lateral flow urine lipoarabinomannan assay (LF-LAM)
- Web Annex 2.5 Low complexity automated NAATs
- Web Annex 2.6 First-line line probe assay (FL-LPA)
- Web Annex 2.7 Second-line line probe assay (SL-LPA)
- Web Annex 2.8 High complexity reverse hybridization-based NAATs

### **Web Annex 3. Evidence-to-decision tables**

- Web Annex 3.1 Xpert MTB/RIF and Xpert Ultra
- Web Annex 3.2 Truenat MTB, MTB Plus, MTB-RIF Dx
- Web Annex 3.3 Moderate complexity automated NAATs
- Web Annex 3.4 Loop-mediated isothermal amplification (TB-LAMP)
- Web Annex 3.5 Lateral flow urine lipoarabinomannan assay (LF-LAM)
- Web Annex 3.6 Low complexity automated NAATs

Web Annex 3.7 First-line line probe assay (FL-LPA)

Web Annex 3.8 Second-line line probe assay (SL-LPA)

Web Annex 3.9 High complexity reverse hybridization-based NAATs

## Web Annex 4. Evidence synthesis and analysis

Web Annex 4.1 Impact of diagnostic test Xpert MTB/RIF on patient-important outcomes for tuberculosis: a systematic review

Web Annex 4.2 Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in adults with signs and symptoms of pulmonary TB: an updated systematic review

Web Annex 4.3 Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in adults with signs and symptoms of extrapulmonary TB: an updated systematic review

Web Annex 4.4 Xpert MTB/RIF and Xpert Ultra for detecting active tuberculosis in children: an updated systematic review

Web Annex 4.5 Systematic literature review of economic evidence for molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB in adults and children

Web Annex 4.6 Report on user perspectives on Xpert testing: results from qualitative research

Web Annex 4.7 Report on the diagnostic accuracy of the Molbio Truenat Tuberculosis and Rifampicin-Resistance assays in the intended setting of use

Web Annex 4.8 Moderate complexity automated NAATs: Diagnostic accuracy for TB detection and detection of resistance to rifampicin and isoniazid. A systematic review and meta-analysis.

Web Annex 4.9 Systematic Literature Review of Economic Evidence for Nucleic acid amplification tests (NAATs) to detect TB and DR-TB in adults and children

Web Annex 4.10 User perspectives on NAATs to detect TB and resistance to anti-TB agents: results from qualitative evidence synthesis (systematic review)

Web Annex 4.11 User perspectives on nucleic acid amplification tests for tuberculosis and tuberculosis drug resistance: (interviews study)

Web Annex 4.12 LF-LAM for detecting active tuberculosis in people living with HIV: an updated systematic review

Web Annex 4.13 Economic evaluations of LF-LAM for the diagnosis of active tuberculosis in HIV-positive individuals: an updated systematic review

Web Annex 4.14 User perspectives on LF-LAM for the diagnosis of active tuberculosis: results from qualitative research

Web Annex 4.15 Low complexity automated NAATs: Diagnostic accuracy for detection of resistance to isoniazid and second-line anti-TB agents. A systematic review

Web Annex 4.16 Drug concentrations used in culture-based drug susceptibility testing for included studies on second-line line probe assays diagnostic accuracy

Web Annex 4.17 High complexity reverse hybridization-based NAATs: Diagnostic accuracy for detection of resistance to pyrazinamide. A systematic review

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23737](https://www.yunbaogao.cn/report/index/report?reportId=5_23737)

